United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for treating high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, the company involved in developing RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. United Therapeutics Corporation was incorporated in 1996 and is headquartered in Silver Spring, Maryland.

United Therapeutics Corporation

United Therapeutics stock was up on Monday after the company announced positive clinical trial results.


What Pushed United Therapeutics Stock (UTHR) Higher Today?

Oppenheimer analyst Andreas Argyrides maintained a Buy rating on United Therapeutics today and set a price target of $650.00. Argyrides covers the ...

Oppenheimer Keeps Their Buy Rating on United Therapeutics (UTHR)

In a report released today, from Cantor Fitzgerald maintained a Buy rating on United Therapeutics, with a price target of $625.00. In addition to C...

Current Quarter	$6.7	Next Quarter	$6.91
Current Year	$27.63	Next Year	$32.84
QoQ Growth	+3.1%	YoY Growth	+18.9%
3Y EPS CAGR	+35.6%	Target Price	$626.92
Consensus	Buy	Upside	+9.1%

Current Quarter Rev	N/A	Next Quarter Rev	N/A
Revenue Growth	N/A	YoY Growth	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	UTHR	$574.77	-1.19%	385.19K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	UTHR	$574.77	-1.2%	385.19K
3
4
5
6

UTHR

UTHR

EPS Estimates Overview

EPS Historical Trend (5 Years)

Quarterly EPS Estimates

Revenue Analysis

Get United Therapeutics Corporation Data in Excel

Get United Therapeutics Corporation Data in Excel